This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Thrombosis	Tissue factor pathway inhibitor (TFPI)	Cell culture and mouse studies suggest that protease-resistant TFPI could help treat thrombosis. In wild-type mice, infusion of recombinant TFPI lacking neutrophil elastase- and cathepsin G-specific proteolytic sites led to less fibrin deposition after carotid injury than infusion of recombinant wild-type TFPI. Next steps could include developing other protease-resistant TFPI variants and testing their antithrombotic efficacy in other animal models of thrombosis.	Patent application filed covering protease-resistant TFPI proteins; licensing status undisclosed	Massberg, S. <i>et al. Nat. Med.</i> ; published online Aug. 1, 2010; doi:10.1038/nm.2184 Contact: Bernd Engelmann, Ludwig Maximilian University of Munich, Munich, Germany e-mail: bernd.engelmann@med.uni-muenchen.de
SciBX 3(34); doi:10.1038/scibx.2010.1037 Published online Sept. 2, 2010				